HBV/HCV Infection Was Not Significantly Independently Associated with COVID-19 Severity: A Meta-Analysis of Confounding Variables-Adjusted Data

Xu, Jie; Wang, Yujia; Feng, Huifen; Liu, Fang; Yang, Haiyan

doi:10.1007/s10620-022-07799-9

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, studies have also shown that anti‐HBV treatments, such as tenofovir disoproxil fumarate (TDF) and entecavir (ETV), may be associated with a reduced risk of SARS‐CoV‐2 infection and may have a positive impact on recovery from COVID‐19 19,20 . Nevertheless, these controversial conclusions indicate a need for further investigation into the underlying interactions between HBV and SARS‐CoV‐2 coinfection 21–23 …”

Section: Introductionmentioning

confidence: 99%

“…19,20 Nevertheless, these controversial conclusions indicate a need for further investigation into the underlying interactions between HBV and SARS-CoV-2 coinfection. [21][22][23] In December 2022, China abandoned its "dynamic zero-COVID" policy and lifted most of the restrictive measures. This policy change led to a rapid surge in Omicron variant infections among the Chinese population within a span of just 2 months around the 2023 new year.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Alleviated symptoms of SARS‐CoV‐2 Omicron variant infection in chronic hepatitis B patients with immune control

Liu,

Zhang,

Kong

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The impact of hepatitis B virus (HBV) infection on the progression of coronavirus disease 2019 (COVID‐19) disease remains controversial. We aimed to investigate whether pre‐existing chronic HBV (CHB) infection and therapy with anti‐HBV nucleos(t)ide analogs (NAs) influence the clinical presentation of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron variant infection. In this study, clinical information was collected via a questionnaire from patients with COVID‐19, and their clinical symptoms were quantitatively assessed for comparative analyses. Additionally, hepatitis B‐related laboratory data were collected for CHB patients. Propensity score matching (PSM) was used to minimize confounding biases. A total of 785 patients with COVID‐19 were included in the cohort, of which 387 were identified as being infected with CHB infection and they were categorized as being in the immune control or clearance phase. After PSM, the CHB group (n = 222) had a shorter duration of fever and disease course, milder clinical symptoms, and lower incidence of pneumonia than the non‐CHB group (n = 222) after Omicron variant infection (p < 0.05). After the adjustment of confounding factors, CHB patients showed a lower risk of prolonged fever, severe clinical symptoms, and pneumonia (p < 0.05). However, there were no statistically significant differences in the clinical symptoms and incidence of pneumonia between CHB patients who received and did not receive NAs, or CHB patients who received tenofovir disoproxil fumarate and entecavir (p > 0.05). In conclusion, our findings suggest that the crosstalk of anti‐HBV immunity may contribute to the alleviated symptoms of SARS‐CoV‐2 Omicron variants infection in the CHB patients, independent of anti‐HBV NA therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Alleviated symptoms of SARS‐CoV‐2 Omicron variant infection in chronic hepatitis B patients with immune control

Liu,

Zhang,

Kong

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

Hepatitis C Virus Infection and COVID-19 Inpatient Mortality

Goble,

Debes

2024

Infect Dis Clin Pract

View full text Add to dashboard Cite

Background The impact of chronic HCV infection on outcomes in patients with COVID-19 remains unclear as studies have showed mixed results. We aimed to determine if HCV infection impacted outcomes in COVID-19 hospitalizations. Methods We retrospectively assessed hospitalizations for COVID-19 in the year 2020 using the National Inpatient Sample database. ICD-10 codes were used to establish a primary diagnosis of COVID-19 and to determine patients with a history of HCV infection. Outcomes were compared between those with and without a history of HCV using logistical regression analysis, controlled for age, sex, and Charlson Comorbidity Index. Results A total of 1,050,720 hospitalizations for COVID-19 were identified, 8040 (0.8%) of which occurred in individuals with a diagnosis of HCV infection. Mortality (OR = 1.04; 95% CI, 0.90–1.22; P = 0.549) and intubation (OR = 1.14; 95% CI, 0.98–1.33, P = 0.092) rates were not significantly increased in patients with a diagnosis of HCV after adjusting for confounders. Mortality was increased in the HCV cohort when it was restricted to those with cirrhosis (adjusted OR = 1.42; 95% CI, 1.05–1.91; P = 0.023) and decompensated cirrhosis (adjusted OR = 2.38; 95% CI, 1.51–3.76, P < 0.001). Conclusions Whereas cirrhosis was associated with mortality in those hospitalized with COVID-19, HCV in the absence of cirrhosis was not a risk factor for COVID-19 mortality.

show abstract

Impact of prior SARS-CoV-2 infection on postoperative recovery in patients with hepatocellular carcinoma resection

Fang,

Wu,

Gan

et al. 2024

BMC Gastroenterol

View full text Add to dashboard Cite

HBV/HCV Infection Was Not Significantly Independently Associated with COVID-19 Severity: A Meta-Analysis of Confounding Variables-Adjusted Data

Cited by 4 publications

References 9 publications

Alleviated symptoms of SARS‐CoV‐2 Omicron variant infection in chronic hepatitis B patients with immune control

Alleviated symptoms of SARS‐CoV‐2 Omicron variant infection in chronic hepatitis B patients with immune control

Hepatitis C Virus Infection and COVID-19 Inpatient Mortality

Impact of prior SARS-CoV-2 infection on postoperative recovery in patients with hepatocellular carcinoma resection

Contact Info

Product

Resources

About